Work Here?
Overview
Cogstate provides digital cognitive assessments to support brain health research and drug development. Its tests are web- or app-based cognitive tasks that patients or trial participants complete, producing standardized scores that researchers can compare against validated benchmarks. Data from the tests is used in biopharma, academia, and clinical settings to measure cognition in trials and care, with accompanying consulting services. Unlike some competitors, Cogstate combines a long history (founded in 1999) with a focused application on cognitive measurement for pharmaceutical clinical trials and mental health/neurological conditions, along with ongoing scientific validation. The company’s goal is to improve the efficiency and reliability of cognitive measurement in research and clinical care to help develop and assess therapies for disorders like depression, schizophrenia, and bipolar disorder.
About Cogstate
Industries
Data & Analytics
Consulting
Enterprise Software
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Australia
Founded
1999
Simplify's Take
What believers are saying
- Medidata partnership integrates Cogstate into AI-powered clinical trial platform ecosystem.
- Expanding mood disorder and neurodegenerative disease focus captures high-value biopharma segments.
- $82M revenue base with 160 employees demonstrates operational efficiency and scalability.
What critics are saying
- AI-native competitors (Clinion, Signant) offer integrated eCOA platforms undercutting standalone tests.
- FDA's 2025 decentralized trial mandate requires real-time AI analytics Cogstate lacks.
- Open-source DeepMind cognitive models enable biopharma to bypass proprietary assessments entirely.
What makes Cogstate unique
- 25-year track record in cognitive assessment with 220 clinicians across 40+ languages.
- Proven profitability: 11% annual EPS growth, EBIT margins expanded 14% to 25%.
- Strategic hires (Dr. Sink, Dr. Lucić) strengthen Alzheimer's and psychiatry trial leadership.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Generous Paid Time-off
401(k) Matching
Health, Dental & Vision Coverage
Short-Term & Long Term Disability Life Insurance
Pre-Tax Benefits
Learning & Development Opportunities
Stock Price
Company News
Cogstate, an ASX-listed technology company, has attracted investor attention due to its profitability and growth trajectory. Over the past three years, the company has grown earnings per share by 11% annually, whilst EBIT margins improved from 14% to 25% alongside revenue growth. The company's performance stands in contrast to loss-making speculative investments, offering a more traditional investment opportunity based on proven profitability. Cogstate's financial sustainability and consistent earnings growth demonstrate its ability to generate returns without the heightened risks associated with pre-revenue companies. Investors are also monitoring insider activity, as insider buying often signals confidence in future share price performance, though this indicator alone does not guarantee success.
New Haven, CT - August 18, 2025 - Cogstate, a leading neuroscience technology company, today announced the appointment of Luka Lucić, PhD, as Senior Director, Clinical Science, Psychiatry.
Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities
Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Cogstate, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies. Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial design decisions, endpoint selection, and data quality considerations for cognitive and clinical outcome assessments
Cogstate Ltd has announced an update to their on-market share buy-back program, reporting the purchase of 9,787 shares on the previous day, adding to a total of 92,203 shares bought back to date.
Cogstate is Hiring for 7 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Cogstate
Industries
Data & Analytics
Consulting
Enterprise Software
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Australia
Founded
1999
Cogstate is Hiring for 7 Jobs on Simplify!
Find jobs on Simplify and start your career today